Ibrutinib
Payments companies reported to CMS as associated with Ibrutinib. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ibrutinib, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ibrutinib
These are the largest totals companies reported as associated with Ibrutinib. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Tapan Kadia | Houston, TX | Internal Medicine | $24,114.61 |
| Elias Jabbour | Houston, TX | Hematology & Oncology | $23,787.41 |
| Hagop Kantarjian | Houston, TX | Medical Oncology | $19,809.60 |
| William Wierda | Houston, TX | Hematology & Oncology | $17,287.00 |
| Nuhad Ibrahim | Houston, TX | Medical Oncology | $16,001.61 |
| Nitin Jain | Houston, TX | Internal Medicine | $14,127.61 |
| Naval Daver | Houston, TX | Hematology & Oncology | $13,419.81 |
| Vamsidhar Velcheti | Jacksonville, FL | Hematology & Oncology | $13,361.52 |
| Rami Komrokji | Tampa, FL | Hematology (Internal Medicine) | $11,777.91 |
Prescribed Ibrutinib?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.